IHS Chemical Week

EnviroTech :: R&D

EU Trails U.S. on Biotech R&D Spending, Capability is Building

3:28 AM MDT | October 19, 2011 | Alex Scott

Europe needs to step up its investment in biotech R&D and establish supportive regulatory policies if it is to keep pace with the U.S. in the biotech sector, says Stephan Tanda, board member for DSM and chairman of industry biotech association EuropaBio. Total biotech R&D spending by publicly traded companies in the U.S. in 2009-2010 was $17.6 billion. This compares with €3.4 billion ($4.7 billion) in Europe during the same period. Tanda made his comments speaking earlier today at The European Forum for Industrial Biotechnology (EFIB) in Amsterdam...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa